[123I]I-DARPIN-Ec1

The study should evaluate the biological distribution of [123I]I-DARPIN-Ec1 in patients with lung and ovarian cancer
The primary objective are:
To assess the distribution of [123I]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals.
To evaluate dosimetry of [123I]I-DARPIN-Ec1.
To study the safety and tolerability of the drug [123I]I-DARPIN-Ec1 after a single injection in a diagnostic dosage.
The secondary objective are:
1. To compare the obtained [123I]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients.